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Severe fever with thrombocytopenia syndrome bunyavirus is
a newly discovered bunyavirus with high pathogenicity to
human. The transmission model has been largely un-
characterized. Investigation on a cluster of severe fever with
thrombocytopenia syndrome cases provided evidence of
person-to-person transmission through blood contact to the
index patient with high serum virus load.
A novel bunyavirus designated severe fever with thrombocyto-
penia syndrome bunyavirus (SFTSV) was recently identiﬁed to be
the etiological cause of severe fever with thrombocytopenia syn-
drome (SFTS) [1]. The SFTS bunyavirus was classiﬁed as a new
member of genus Phlebovirus,f a m i l yBunyaviridae exception to
pathogenicornonpathogenicgroupsinthegenus.Although ticks
of the species Haemaphysalis longicornis were supposed to be
the vector of SFTSV infection to humans [1], most patients
reported none or unclear tick-bite history before their onset of
SFTS. Thus,the riskfactors ofSFTStransmission remain unclear.
A thorough review of literature did not ﬁnd any reports on
person-to-person transmission of phleboviruses. As for viruses
in the family Bunyaviridae, person-to-person transmission of
bunyavirus has so far been reported only for 2 viruses: Crimean-
Congo hemorrhagic fever virus (CCHFV), a widespread tick-
borne nairovirus spread through blood contacts [2, 3], and the
human-to-human transmission of CCHFV, which occurs as
nosocomial infections; and the Andes virus, a hantavirus causing
hantavirus pulmonary syndrome in South America, which was
documented to be transmitted through aerosol under certain
circumstances [4, 5] (transmission occurred during the pro-
dromal phase of the illness without bleeding of the index patient).
The infected cases of SFTSV commonly showed a sporadic dis-
tribution with no relationship among cases. Here, we report re-
sults of an investigation into a cluster of SFTS patients occurred in
Shandong province, a SFTS endemic area of China.
METHODS
Descriptive investigation of a cluster of 5 SFTS cases following
exposure to an index patient who died from the disease was
performed. A 77-year-old male farmer who died from SFTS was
deﬁned as the index patient in the cluster. Five other cases in the
cluster included a 32-year-old male intensive care unit (ICU)
physician (Case 1), a 48-year-old male ICU consultation physi-
cian (Case 2), a 42-year-old younger son of the index patient
(Case 3), and a 45-year-old older son of the index patient (Case
4), as well as a 43-year-old male mortuary beautician (Case 5).
The investigation included a review of circumstances and med-
ical records, specimen collection, virus isolation, real-time poly-
merase chain reaction for viral RNA detection [6], and sequencing
and serological tests (capture enzyme-linked immunosorbent
assay [ELISA] for immunoglobin [Ig] M antibody, antigen
sandwich ELISA for IgG antibody, and microneutralization tests
[MNT]) [7]. As for risk assessment of transmission factors, all
contactors of the index patient during the period from the
beginning (25 September 2010) to the end (8 October 2010) were
classiﬁed through 3 types of contacts, including blood, droplet,
and possible airborne contacts. The investigation was reviewed
and approved by the ethics committee of China Center for Disease
Control and Prevention (CDC), which uses international guide-
lines to ensure conﬁdentiality, anonymity, and informed consent.
RESULTS
The index patient was from an SFTS-endemic region and ﬁrst
had onset of illness on 25 September 2010; was admitted to
a local hospital on 28 September with a high fever of 39.5Ca n d
vomiting; and the infection was identiﬁed through initial
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evated aspartate aminotransferaselevel. The patient was diagnosed
as a suspected SFTS case, and transferred to the intensive care unit
the next day, where he received ribavirin, dexamethasone, ome-
prazole, and cryoprecipitation for therapy. On 2 October 2010, his
condition deteriorated with hypersomnia, shortness of breath, and
mouth mucosal bleeding. On 3 October, he appeared confused
a n ds h o w e dd y s p n e a ,t h e nw a si n t u b a t e da n dm e c h a n i c a l
ventilated. On 4 October, the patient was in shock and co-
matose, developed disseminated intravascular coagulation
and multiple organ dysfunction syndrome, and died the next day.
An important observation was that the index patient had unique
hemorrhagic symptoms, including bleeding from mouth mucosa,
gastrointestinal lumen, and lungs, which was rare in previously
identiﬁed SFTS patients [1]. The patient’s fever remained high
(39C–40C) until death, although lowered somewhat by giving
dexamethasone. Clinical laboratory values (Table 1) showed un-
usually high level of tissue enzymes, blood urea nitrogen, and
creatinine, which might indicate impaired liver, heart, and kidney
functions. Consistent with the largely reduced platelet count, the
index patient had a signiﬁcantly elongated activated partial
thromboplastin time, which represented a largely impaired co-
agulation function. Immediately after death, the corpse was
transferred to the patient’s home in a local village for a funeral
ceremony, then transferred to a crematorium 3 days later.
Epidemiologic investigations began with interviews with 5
secondary SFTS patients and 58 other individuals who had ex-
posure to the index patient from onset of the illness until cre-
mation. We found that all 5 secondary cases had possible blood
contact through skin or mucosa. Case 1, the local ICU doctor,
performed the intubation for the index patient, resuscitating the
patient before his death. He had general surgical protection but
withoutaprotectivefaceshieldorgoggles.Case2,theconsultant
doctor, traveled from a nonendemic area to the local hospital
for a medical consult with the patient, and the patient’s blood
dropped on his hand when he was helping an ICU nurse draw
Table 1. Laboratory Analysis of a Cluster of Severe Fever With Thrombocytopenia Syndrome Patients in China
Index Patient Case 1 Case 2 Case 3 Case 4 Case 5
Clinical tests
a
Platelet count 21 69 32 38 77 84
White-cell count 1.03 2.18 1.23 1.54 1.35 2.30
ALT 126 89 146 166 107 92
AST 543 57 140 186 66 64
LDH 2213 207 578 605 210 199
Proteinuria
b 1 1 1 21122
Hematuria
b 1 1 1 22222
APTT 101.2 47.0 63.5 87.1 44.7 45.2
Laboratory ﬁndings
Virus isolation Yes No Yes Yes No No
Viral RNA (copies/mL)
c 3.55 3 10
10 2.42 3 10
4 9.00 3 10
3 4.10 3 10
3 7.13 3 10
3 3.43 3 10
3
Virus load (TCID50/mL)
d 9.67 3 10
7 6.60 3 10
1 2.45 3 10
1 1.12 3 10
1 1.94 3 10
1 9.33 3 10
0
IgM antibody
e,h ,10 640 5120 5120 640 5120
IgG antibody
f,h N/A 640 5120 2560 2560 640
MNT
g,h N/A 40 40 40 40 10
Risk factors
i
Blood (P , .001) N/A Yes Yes Yes Yes Yes
Droplet (P 5 .192) N/A Yes No No No No
Possible airborne (P 5 .434) N/A No No Yes Yes Yes
a ALT, alanine aminotransferase; AST, aspartate aminotransferase; LDH, lactate dehydrogenase; APTT, activated partial thromboplastin time.
b 2, negative; 1, weak positive; 111, strong positive.
c Viral RNA copies were calculated according to standard reaction curves, which were established using serially diluted in vitro RNA transcripts as standard samples.
d Virus load was determined based on an average conversion coefﬁcient between virus copies and virus titer presented as 50% tissue culture infective dose
(TCID50/mL).
e Serum samples collected in the acute phase were subjected to immunoglobin (Ig) M detection with IgM antibody capture enzyme-linked immunosorbent assay
(ELISA),withhorseradishperoxidase–conjugatedrecombinantseverefeverwiththrombocytopeniasyndromebunyavirus(SFTSV)nucleoproteinasthedetectionagent.
f Serum samples collected in the convalescent phase were subjected to IgG detection with sandwich ELISA by using recombinant SFTSV nucleoprotein as the
detection agent.
g MNT, microneutralization test.
h Values for IgM antibodies, IgG antibodies, and MNT are the reciprocals of the serum dilution.
i Risk factors were assessed using logistic regression analysis; P , .05 was considered to be statistically different. Deﬁnition of risk factors was described in the
Results section.
250 d CID 2012:54 (15 January) d BRIEF REPORTblood without wearing gloves. Case 3, the younger son of the
index patient, was a long-distance truck driver not living in the
same village, and directly touched the blood ﬂowing from the
deceased patient’s mouth and nose when he cried on the corpse.
Case 4, the older son of the index patient, was also a long-
distance truck driver, and took care of the dead body and was
wiping off the blood from the face of the corpse. Case 5, a local
mortuary beautician, did the make-up for thecorpse with gloves
and mask, but took them off twice during the procedure. The
above 5 cases all developed the disease 7–15 days after exposure,
with only 3 of them having contact with blood after death. In
comparison with the index patient, all 5 secondary cases had
minor clinical features (Table 1), without obvious hemorrhagic
manifestations, so they did not receive dexamethasone therapy.
Exceptfor the major riskfactorof blood contact,droplet contact
(N 5 4), which included 3 medical staff who were involved in
the intubation and the index patient’s daughter who cared for
him before death, was assessed as the second possible risk factor.
In addition, the risk factor of possible airborne transmission
(being in the ICU room or funeral room without mask pro-
tection) was also assessed among all 63 exposed individuals. Of
them, the medical doctors and nurses (N 5 16) were with
protection; and the others were without (N 5 47), including
ICU patients who were staying in the same room (N 5 8),
family members (N 5 3), and visitors to the funeral room
where the corpse was kept (N 5 35). The multivariate analysis
(logistic regression analysis) showed that blood contact was the
most likely mode of transmission (P , .001; Table 1).
It is noticeable that the serum collected from the index pa-
tient on the day he died contained a relatively high amount of
SFTSV, which reached about 3.55 3 10
10 viral RNA copies/mL
(calculated as 9.67 3 10
7 50% tissue culture infective dose
[TCID50]/mL). This number was about 100 000-fold higher
than viral copies detected in the serum samples of the 5 sec-
ondary patients, which ranged from 10
3 to 10
5 copies/mL
(Table 1). All 5 patients had virus-speciﬁc IgM antibodies in
the acute phase, and elevated virus-speciﬁc immunoglobin G
(IgG) antibodies in the convalescent phase. The index patient,
however, had minimal or undetectable levels of virus speciﬁc
IgM antibodies on day 11 after onset of fever (Table 1).
Compared with the entire genomic sequence of the virus strain
isolated from the index patient, Cases 2 and 3 were nearly 100%
identical, and provided genetic evidence for the epidemic
ﬁndings on the possible transmission of SFTSV from the index
patient to secondary patients.
DISCUSSION
Here, we reported the person-to-person transmission of SFTSV
with a cluster of 6 SFTS patients that occurred in Shandong
Province of eastern China. Investigation studies revealed that all
5secondaryinfectedpatientshadpossiblecontactwiththeindex
patient’sblood.Ofthem,onlyCase1 (ICUdoctor)hadevidence
of droplet contact contamination (during intubation) but not
blood contact, but we included him also as a blood contactor
because he performed intubation without protective face shield
and goggles, therefore he had an extremely high risk of blood
contact through unprotected skin and mucosa. The risk as-
sessment revealed that blood contact was the major risk factor
for the human-to-human transmission of SFTSV. Additionally,
3 secondary patients who only had contact with the index pa-
tient after death were still infected, which indicated that SFTSV-
infected blood may remain infectious for a long time, even after
patient death.
It is notable that the level of virus copies in the index pa-
tient’s serum was extremely high, but with no detectable IgM
or IgG antibodies, which suggested that his immune responses
to limit the replication of SFTSV were severely impaired. The
patient had no immune system disease, thus the minimal
immune responses might be due to the early and sustained
application of glucocorticoid, which has a side effect of re-
pressing immune functions [8]; clinical physicians should take
note of this ﬁnding.
Clinically, SFTS is easily confused with hemorrhagic fever
with renal syndrome caused by hantavirus [9] and human an-
aplasmosis [10]. The hantavirus-speciﬁc IgM antibodies were
not detected in the SFTS patients’ serum samples (data not
show). Due to the limitation of our study, we were not able to
detect Rickettsia infection, which was previously reported in
outbreaks of nosocomial infections [10]. However, the methods
we used for diagnosis of SFTS patients were well validated [1],
and the human-to-human transmission of SFTSV we described
in this study could not simply be classiﬁed as being nosocomial
transmission; specially, 3 of the 5 secondary cases that occurred
in the household. Additionally, the lessons of person-to-person
transmission of SFTSV we learned from this study highlighted
the necessity of establishing standard precautions for avoiding
direct contact and blood-based transmission.
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